Bachem has entered a collaboration with Eli Lilly and Company to develop and manufacture active pharmaceutical ingredients (APIs) based on oligonucleotides, a rising new class of complex molecules. Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology. Furthermore, Bachem will provide R&D and production personnel at its facilities in Bubendorf, Switzerland, for the ...